转移性肾细胞癌治疗与生存的差异
基于美国国家癌症数据库2004至2015年31989例转移性肾细胞癌患者,分析种族、性别和社会经济因素对系统治疗和减瘤性肾切除术使用及生存的影响。女性接受系统治疗几率较低,非西班牙裔黑人和西班牙裔接受减瘤性肾切除术几率较低,黑人接受系统治疗几率较低且死亡风险较高;校正治疗接受情况后生存差异消失。
要点
- 女性接受系统治疗几率较低(OR 0.91,P<.01),未接受治疗几率较高(OR 1.14,P<.01)。
- 非西班牙裔黑人(OR 0.75,P<.01)和西班牙裔(OR 0.86,P=.01)接受减瘤性肾切除术几率较低。
- 黑人接受系统治疗几率较低(OR 0.85,P<.01),未治疗几率较高(OR 1.41,P<.01),死亡风险较高(HR 1.06,P=.03)。
核心结论
- 转移性肾细胞癌的治疗存在种族、性别和社会经济差异,这些差异与总生存差异相关。
- 消除系统性障碍和改善医疗可及性可能减少差异并改善转移性肾细胞癌的结局。
研究设计与样本
- 基于美国国家癌症数据库(2004-2015年)的回顾性分析,纳入年龄≥18岁诊断为转移性肾细胞癌的患者共31989例。
- 使用多因素逻辑回归评估与系统治疗和减瘤性肾切除术使用相关的因素,使用Cox比例风险回归评估总生存。
主要发现
- 全部患者中30.2%接受减瘤性肾切除术,51.6%接受系统治疗,25.8%未接受治疗。
- 女性接受系统治疗的几率较低(OR 0.91,P<.01),未接受治疗的几率较高(OR 1.14,P<.01)。
- 非西班牙裔黑人接受减瘤性肾切除术的几率较低(OR 0.75,P<.01),西班牙裔接受减瘤性肾切除术的几率较低(OR 0.86,P=.01)。
- 黑人接受系统治疗的几率较低(OR 0.85,P<.01),未接受治疗的几率较高(OR 1.41,P<.01)。
- 校正人口学和疾病变量后,黑人死亡风险较高(HR 1.06,P=.03),主要由于较少使用系统治疗和减瘤性肾切除术;校正治疗接受情况后生存差异消失(HR 0.99,P=.66)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate racial, gender, and socioeconomic differences in the treatment of metastatic renal cell carcinoma (mRCC) and their impact on survival. METHODS: Patients aged ≥18 years diagnosed with mRCC in the National Cancer Database (2004-2015) were analyzed. Multivariable logistic regression models were used to evaluate factors associated with systemic therapy and cytoreductive nephrectomy (CN) utilization. Cox proportional hazards regression models were used to evaluate overall survival. RESULTS: In total, 31,989 patients with mRCC were identified with 30.2% receiving CN, 51.6% receiving systemic therapy, and 25.8% receiving no treatment. Females were at lower odds of receiving systemic therapy (OR 0.91, P <.01) and increased odds of no treatment (OR 1.14, P <.01). Non-Hispanic Black and Hispanic patients were at decreased odds of receiving CN (OR 0.75, P <.01 and OR 0.86, P = .01, respectively). Black patients were at decreased odds of receiving systemic therapy (OR 0.85, P <.01) and increased odds of no treatment (OR 1.41, P <.01). Adjusting for demographic and disease variables, Black patients were at increased risk of death (HR 1.06, P = .03), largely due to less use of systemic therapy and CN; survival differences disappeared after accounting for receipt of therapy (HR 0.99, P = .66). CONCLUSION: There are racial, gender, and socioeconomic differences in the treatment of mRCC which are associated with a disparity in overall survival. Dismantling systemic barriers and improving access to care may lead to reduced disparities and improved outcomes for mRCC.
引用
- Metcalf MR, Peña VN, Cheaib JG, et al. Disparities in the Treatment and Survival of Metastatic Renal Cell Carcinoma. Urology. 2021. PMID: 34808140. doi:10.1016/j.urology.2021.08.070
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。